



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Chang Yi Wang
Serial No. : 09/865,294
Filed : May 25, 2001
For : IMMUNOGENIC PEPTIDE COMPOSITION FOR THE PREVENTION
AND TREATMENT OF ALZHEIMERS DISEASE
Group Art Unit : 1647
Examiner : Sharon Turner, Ph.D.

Commissioner for Patents
Washington, D.C. 20231

Box: Non-fee Amendment

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This is in response to the office action dated October 21, 2002, for which a shortened period of one month was set.

Applicant received a call from Dr. Sharon Turner indicating that there has been a change and that she is now the Examiner assigned to this application. Restriction requirement was discussed. Applicant pointed to Table 3 and 4 showing the various embodiments of the invention. Pursuant to the discussion, this is a response to the pending species election requirement.

Please amend the application as follows:

Amend the Sequence Listing by adding SEQ ID NO:77, the sequence for the linker Pro-Pro-Xaa-Pro-Xaa-Pro. Attached is a substitute Sequence Listing with the added sequence, SEQ ID NO:77.

In the Specification

Page 17-18, [0043]:

[0043] Preferably, the N terminal fragment of the A β ₁₋₄₂ peptide is selected from the group consisting of SEQ ID NOS: 66-69 and an immunologically effective analog thereof. The Th peptide is covalently attached to either the N- or C-terminus

B1

RECEIVED
NOV 04 2002
TECH CENTER 1600/2800

8/B
Mg. J
11/7/02